Table 5 Association between pathological complete response (pCR) and breast cancer intrinsic subtype.
From: Biomarker dynamics and prognosis in breast cancer after neoadjuvant chemotherapy
Luminal A (incidence/total cases) | Luminal B HER2+ (incidence/total cases) | Luminal B HER2− (incidence/total cases) | HER2+ (incidence/total cases) | Triple negative (incidence/total cases) | ||
|---|---|---|---|---|---|---|
2003–2009 | pCR | 4.3% (1/23) | 7.7% (1/13) | 6.7% (1/15) | 30.8% (4/13) | 7.1% (1/14) |
2010–2017 | pCR | 5.8% (3/52) | 41.4% (24/58) | 17.2% (5/29) | 46.8% (22/47) | 54.7% (41/75) |
2003–2017 | pCR | 5.3% (4/75) | 35.2% (25/71) | 13.6% (6/44) | 43.3% (26/60) | 47.2% (42/89) |
